Evidence map›Paper›PMID 41489091›Full record

ArticleJournal of magnetic resonance imaging : JMRI2026

Evaluation of Image-Level Harmonization Methods for Multi-Center MR Neuroimaging.

Brandon C Ho, Donghoon Kim, Ashwin Kumar, Skylar Weiss, Hillary Vossler, Elizabeth Mormino, Greg Zaharchuk, Alzheimer's Disease Neuroimaging Initiative

Abstract readMulticenter Study
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brandon C HoDepartment of Radiology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0009-0002-1202-2613
Donghoon KimDepartment of Radiology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-5479-2707
Ashwin KumarDepartment of Radiology, Stanford University, Stanford, California, USA.
Skylar WeissDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
Hillary VosslerDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
Elizabeth MorminoDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
Greg ZaharchukDepartment of Radiology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0001-5781-8848
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Lisa Goldman Rosas · 2020 to 2026
$29.0M
Predicting Tissue and Functional Outcome in Acute StrokeR01NS130172 · NINDS · STANFORD UNIVERSITY · PI Gregory George Zaharchuk · 2023 to 2026
$2.4M
AI-Enhanced Brain PET Imaging for Alzheimer's DiseaseR56AG071558 · NIA · STANFORD UNIVERSITY · PI ZAHARCHUK, GREGORY GEORGE · 2022 to 2023
$1.6M
AbbVieAlzheimer's AssociationAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica Inc.BiogenBristol-Myers Squibb CompanyCereSpir Inc.Cogstate; Eisai Inc.Department of Defense W81XWH-12-2-0012Elan Pharmaceuticals Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche Ltd.FujirebioGE HealthcareGenentech Inc.IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development LLCJohnson & Johnson Pharmaceutical Research & Development LLC.LumosityLundbeckMerck & Co. Inc.Meso Scale Diagnostics LLC.NeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS P30 AG066515NIA NIH HHS R56 AG071558NIA NIH HHS U01 AG024904NIBIB NIH HHSNIH HHS P30AG066515-06NIH HHS U01 AG024904NINDS NIH HHS R01 NS130172Novartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itself

Abstract

backgroundMulti-center imaging studies create large-scale data that are useful for identifying pathological patterns and robust training of deep learning models. However, variation due to site and scanner differences can confound analyses, emphasizing the need for harmonization. PURPOSE: To evaluate scanner-related differences in T1w and T2-FLAIR images in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and assess the performance of publicly available image-level harmonization tools. STUDY TYPE: Retrospective. POPULATION: Scanner group analysis: 1143 ADNI3 subjects (233 GE, 173 Philips, 250 Siemens, with 487 Siemens subjects used as an independent reference group). Within-subject comparison: paired multi-vendor scan sessions from 8 subjects. FIELD STRENGTH/SEQUENCE: 3.0T, T1w, and T2-FLAIR MRI sequences. ASSESSMENT: Gray/white matter contrast ratio (G/W ratio), white matter hyperintensity (WMH) volume, and image feature similarity metrics (Fréchet Inception Distance [FID], Learned Perceptual Image Patch Similarity [LPIPS]) were compared across scanner vendors before and after harmonization with statistical (ComBat) and deep learning (HACA3) algorithms. STATISTICAL TESTS: One-way ANOVA and post hoc Games-Howell tests were conducted to assess differences between scanner groups across image pipelines (baseline, post-harmonization). Repeated-measures ANOVA and post hoc paired t-tests with Bonferroni correction were used to evaluate similarity metric changes pre- and post-harmonization for multi-vendor subjects. We defined statistical significance as p < 0.05.

resultsAt baseline, significant image differences in G/W ratio and WMH volumes between vendors were identified. Both ComBat and HACA3 harmonization improved G/W ratio consistency for T1w and T2-FLAIR imaging across vendors, particularly for GE T2-FLAIRs. HACA3 led to the best similarity between scanner datasets: mean FID T1w/T2-FLAIR: 10.45/14.62 (Baseline); 7.45/11.71 (ComBat); 5.60/8.91 (HACA3). Only HACA3 harmonization resulted in non-significant differences between vendors for WMH volume. DATA

conclusionHACA3 deep learning harmonization outperformed a statistical method, ComBat, improving MR contrast consistency and feature similarity across vendors. However, difficulties in harmonizing T2-FLAIRs highlight limitations in current multi-contrast MR harmonization tools. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 1.

Indexed as

Alzheimer DiseaseImage Processing, Computer-AssistedMagnetic Resonance ImagingNeuroimagingAgedAged, 80 and overAlgorithmsBrainDeep LearningFemaleGray MatterHumansImage Interpretation, Computer-AssistedMaleReproducibility of ResultsRetrospective StudiesAlzheimer's diseaseharmonizationneuroimagingscanner variability

Identifiers

PMID41489091
PMCPMC12980808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.